Summary Radiomedix Inc (Radiomedix) is a biotechnology company that develops and commercializes radiopharmaceuticals for diagnosis and therapy of cancer.The company’s products include radioisotopes, fully automated synthesizers, semi-automated synthesizers, GMP cassettes and consumables, smartmedix system and glucomedix, among others.
Radiomedix’s services include radiochemistry and drug design service, CGMP drug manufacturing suite and microPET imaging laboratory.The company has developed its own chelation technology and new imaging conjugates to improve diagnosis and treatment monitoring for a variety of cancers.
It also develops radiolabeled agent that targets hedgehog signaling pathway and can be used in diagnosis and staging of lung, ovarian, breast, gastrointestinal, hematological, prostate, skin cancer, and others.The company serves nuclear medicine researchers and clinicians.
Radiomedix is headquartered in Houston, Texas, the US.
Radiomedix Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The global macular degeneration treatment market was valued at USD 7,755 million in 2020, and it is expected to reach USD 11,492 million by 2026, registering a CAGR of 6.9% during the period of 2021-2026. The COVID-19 pandemic had a potential economic impact and implications on most of the sectors, including the pharmaceutical and biotech...
The manufacturing execution system market is expected to grow from USD 11.5 billion in 2021 to USD 17.1 billion by 2026 at a CAGR of 8.3% from 2021 to 2026. A few key factors driving the growth of this market include increasing use of industrial automation in process and discrete industries, increasing IT and OT convergence, and the need for...
The North America advanced planning and scheduling (APS) software market is expected to grow from US$ 546.51 million in 2020 to US$ 1,033.86 million by 2028; it is estimated to grow at a CAGR of 8.4% from 2021 to 2028. The growing adoption of cloud-based solutions is expected to escalate the North America advanced planning and scheduling (APS)...
As the global chemicals industry is at the onset of the recovery phase, companies are focusing on identifying and monetizing new opportunities in the industry. The majority of the chemical industries are likely to record volume growth of 4% to 8% in the short term, depending on the chemical sub-segment and product portfolio. A large volume...
The analyst presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the market’s maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs,...
The Europe advanced planning and scheduling (APS) software market is expected to grow from US$ 386.70 million in 2020 to US$ 769.14 million by 2028; it is estimated to grow at a CAGR of 9.1 % from 2021 to 2028. The growing need to enhance overall production process is expected to escalate the Europe advanced planning and scheduling (APS) software...
The Middle East and Africa microplate readers market is expected to reach US$ 19.79 million by 2027 from US$ 16.24 million in 2019; it is estimated to grow with a CAGR of 2.6% from 2020 to 2027. The growth of the market is attributed to some key driving factors such as increasing incidence of infectious diseases and consistent research in...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.